Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finotonlimab perioperative therapy in locally advanced head and neck squamous cell carcinoma
ChiCTR2600117055Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of finotonlimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 2-year event-free survival (EFS) rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
finotonlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600117055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117055.